| Previous Close | 0.6500 |
| Open | 0.6500 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 1400 |
| Day's Range | 0.6411 - 0.6650 |
| 52 Week Range | 0.4700 - 2.9990 |
| Volume | 55,521 |
| Avg. Volume | 252,004 |
| Market Cap | 45.134M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
WARREN, N.J., June 13, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that.
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) on Wednesday, May 29, 2019, from 12:00 – 1:30 PM ET in New York City. The meeting will feature a presentation by Steven D. Nathan, M.D., F.C.C.P., from Inova Fairfax Hospital, who will discuss the current treatment landscape and unmet medical need for patients with PH-ILD.
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) as a late-breaking oral presentation at the American Thoracic Society (ATS) 115th International Conference in Dallas. The ability of INOpulse to improve moderate to vigorous physical activity, or MVPA, as well as other activity parameters, such as overall activity and caloric expenditure, is a significant finding,” said Dr. Nathan.
Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory.
WARREN, N.J., May 09, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing.
WARREN, N.J., March 14, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary.
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The Company’s Chairman, Jonathan M. Peacock, and directors Naseem Amin and Ted Wang each purchased shares in the offering. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are $7 million, assuming no exercise of the underwriter’s option to purchase additional shares.
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Bellerophon expects to receive aggregate gross proceeds of $7 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Bellerophon also intends to grant the underwriter a 45-day option to purchase additional shares of its common stock equal to 15% of the shares to be sold in the offering to cover over-allotments, if any. Bellerophon intends to use the net proceeds from this offering to fund working capital and other general corporate purposes and pursuit of our other research and development efforts. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 6, 2018.
WARREN, N.J., Jan. 07, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.
WARREN, N.J., Nov. 07, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Tesla shares were hammered on Friday after CEO Elon Musk revealed to the New York Times that the stress of his job is getting to him. Shares of Bellerophon Therapeutics saw unusual activity, climbing over 20% despite any news. Tesla, Inc. shares plummeted nearly 9% on Friday.